Strategies to address non-proportional hazards between survival curves - Lessons from phase III trials in hepatocellular carcinoma

Ezequiel Mauro; Tiago B. R. Castro; Marcus Zeitlhoefler; Allan Hackshaw; MinJae Lee; Tim Meyer; Amit G. Singal; Josep M. Llovet

doi:10.1016/j.jhep.2025.08.042

Article2025

OS-060-YI Phase III trials in hepatocellular carcinoma: IMbrave 050 and strategies to address non-proportional hazards

Ezequiel Mauro, Tiago B. R. Castro, Marcus Zeitlhoefler, Allan Hackshaw, MinJae Lee, Tim Meyer, Amit Singal, Josep M. Llovet

Journal of Hepatology

Article2026

Reply to Beyond binary classification of non-proportional hazards: methodological considerations for interpreting pivotal HCC trials

Ezequiel Mauro, Amit Singal, Josep M. Llovet

Article2021

Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study

Richard S. Finn, Masatoshi Kudo, Ann‐Lii Cheng, Lucjan Wyrwicz, Roger K.C. Ngan, Jean–Frédéric Blanc, Ari David Baron, Arndt Vogel, Masafumi Ikeda, Fabio Piscaglia, Kwang–Hyub Han, Shukui Qin, Yukinori Minoshima, Michio Kanekiyo, Min Ren, Ryo Dairiki, Toshiyuki Tamai, Corina E. Dutcus, Hiroki Ikezawa, Yasuhiro Funahashi, T.R. Jeffry Evans

Preprint2024

Data from Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study

Richard S. Finn, Masatoshi Kudo, Ann‐Lii Cheng, Lucjan Wyrwicz, Roger K.C. Ngan, Jean–Frédéric Blanc, Ari David Baron, Arndt Vogel, Masafumi Ikeda, Fabio Piscaglia, Kwang–Hyub Han, Shukui Qin, Yukinori Minoshima, Michio Kanekiyo, Min Ren, Ryo Dairiki, Toshiyuki Tamai, Corina E. Dutcus, Hiroki Ikezawa, Yasuhiro Funahashi, T.R. Jeffry Evans

Article2015

Objective response by mRECIST to predict survival in hepatocellular carcinoma: A multivariate, time-dependent analysis from the phase III BRISK-PS study.

Josep M. Llovet, Joong‐Won Park, Ferrán Torres, Thomas Decaens, Éveline Boucher, Jean‐Luc Raoul, Masatoshi Kudo, Charissa Chang, Valérie Boige, Éric Assenat, Yoon‐Koo Kang, Ho-Yeong Lim, Ian Walters, Riccardo Lencioni

Journal of Clinical Oncology

Strategies to address non-proportional hazards between survival curves - Lessons from phase III trials in hepatocellular carcinoma

Discussion(0)

Related publications

OS-060-YI Phase III trials in hepatocellular carcinoma: IMbrave 050 and strategies to address non-proportional hazards

Reply to Beyond binary classification of non-proportional hazards: methodological considerations for interpreting pivotal HCC trials

Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study

Data from Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT Study

Objective response by mRECIST to predict survival in hepatocellular carcinoma: A multivariate, time-dependent analysis from the phase III BRISK-PS study.